Aug. 06, 2025
What if we could treat hearing loss before it shows up on a standard audiogram? Celia Belline, CEO and co-founder of Cilcare, shares progress on the company’s lead compound, CIL001, developed to treat cochlear synaptopathy—often referred to as hidden hearing loss. A Phase 2A clinical trial is planned to begin later this year, targeting individuals with type 2 diabetes who

















